TICKERNERD
Menu
INMDINMDHealthcare · Medical Devices

INMD Stock Forecast: InMode Ltd. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$14
+0.50% on the day

The 5 Wall Street analysts covering InMode Ltd. hold a median 12-month price target of $17 — +17.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 8 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$805.0M
Ticker Nerd rank
75 / 100
Median analyst target
$17
Analysts covering
5
Revenue$95.6M−0.0% y/y
Operating income$12.3M
Net income$17.1M
Free cash flow$20.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.2%
1M
−4.9%
YTD
−4.2%
1Y
−6.4%
From 52W high
−15.3%
From 52W low
+10.3%
$13
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores InMode Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
75 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
100
Issuance
93
Volatility
88
Quality
69
Accruals
53
Momentum
47
Size
47
Revisions
44
Growth
32

Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (32): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$13$14$15$16$17Jan 26Apr 26Jul 26Oct 26INMDHigh $17Median $17Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
0 Buy5 Hold0 Sell
Low $15Median $17High $17

The green dot is the last close — the median target sits +17.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 May 2026BairdMaintainsNeutral—
7 May 2026BairdMaintainsNeutral$17 → $14
7 May 2026BarclaysMaintainsOverweight—
7 May 2026BarclaysMaintainsOverweight$21 → $19
17 Dec 2025Canaccord GenuityMaintainsHold—
6 Nov 2025UBSMaintainsNeutral—
10 Oct 2025Canaccord GenuityMaintainsHold—
10 Oct 2025NeedhamReiteratesHold—
30 July 2025BarclaysMaintainsOverweight—
30 July 2025NeedhamReiteratesHold—
11 July 2025Canaccord GenuityMaintainsHold—
30 Apr 2025BarclaysMaintainsOverweight—
29 Apr 2025BTIGDowngradeNeutral—
29 Apr 2025Canaccord GenuityMaintainsHold—
29 Apr 2025UBSMaintainsNeutral—
28 Apr 2025NeedhamReiteratesHold—
14 Apr 2025JefferiesMaintainsHold—
14 Apr 2025NeedhamReiteratesHold—
9 Apr 2025NeedhamReiteratesHold—
5 Feb 2025BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

INMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, InMode Ltd. returned −6.4% against +16.2% for the S&P 500, dividends included.

INMD vs S&P 500, last 12 monthsTotal return, rebased to 100
859095100105110115120Jan 26Apr 26Jul 26Oct 26INMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−2.1%
Analysts raising
1
Analysts cutting
3
Fundamentals

InMode Ltd. (INMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
11.6×

Cheaper than 54% of US stocks

Price / sales
2.1×

Cheaper than 50% of US stocks

Price / book
1.3×

Cheaper than 61% of US stocks

EV / EBITDA
4.6×

Cheaper than 54% of US stocks

Growth & margins
Revenue growth (YoY)
16.5%

Higher than 65% of US stocks

Earnings growth (YoY)
−36.2%

Higher than 14% of US stocks

Gross margin
74.8%

Higher than 87% of US stocks

Operating margin
12.8%

Higher than 69% of US stocks

Net margin
20.7%

Higher than 83% of US stocks

Returns & dividend
Return on equity
12.3%

Higher than 69% of US stocks

Return on assets
6.2%

Higher than 82% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

InMode Ltd. (INMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • InMode Ltd. has a market value of $805.0M and an enterprise value of $327.4M.

  • Revenue in the twelve months to 30 June 2026: $374.6M. The latest quarter grew 16.5% year on year.

  • Net income over the same four quarters: $77.5M, a 20.7% net margin.

  • Diluted earnings per share, trailing twelve months: $1.23.

  • Free cash flow in the twelve months to 30 June 2026: $82.5M.

  • InMode Ltd. spent $87.8M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 57.5M.

  • Trailing P/E: 11.6×; forward P/E: 10.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • InMode Ltd. employs 660 people — $568K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

INMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
INMDInMode Ltd.$805.0M
75
AHCOAdaptHealth Corp.$824.3M
44
SIBNSI-BONE, Inc.$833.0M
73
VREXVarex Imaging Corp.$774.3M
83
QDELQuidelOrtho Corp.$846.3M
33
CBLLCeribell, Inc.$858.8M
38
BBNXBeta Bionics, Inc.$917.5M
37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own InMode Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INMD news & analysis

InMode: Hope Is Not An Effective Investment Strategy, But Neither Is Despair

Seeking Alpha · 26 Sept 2026neutral

Seeking Alpha covers InMode as shares remain rangebound amid declining US platform sales, though international growth and recurring consumables revenue provide some stabilization. The author maintains a 'buy' rating (downgraded from 'strong buy'), citing cyclical industry softness, macro headwinds, and frustrations with management's capital allocation, while noting the company's robust net cash, aggressive buybacks, and proprietary technology.

Why it matters — InMode watchers would care because the piece balances the company's financial strengths and stabilization factors against lingering leadership doubts and execution risk that continue to weigh on sentiment.

InMode Advances RF Microneedling Comfort with the Launch of Morpheus8 Cool

PRNewsWire · 9 Sept 2026positive

InMode Ltd. announced the launch of Morpheus8 Cool, a new product aimed at improving patient comfort during RF microneedling procedures. The announcement was made from Irvine, California on Sept. 9, 2026.

Why it matters — The launch expands InMode's aesthetic device portfolio with a comfort-focused enhancement to its established Morpheus8 platform, potentially strengthening its product lineup.

Steel Partners Urges InMode Shareholders to Vote AGAINST the Re-Election of Dr. Hadar Ron and AGAINST Extraordinary Special Committee Compensation at the July 30 Annual General Meeting

Business Wire · 28 July 2026negative

Steel Partners, a significant shareholder of InMode, issued a letter urging shareholders to vote against Proposal 1 (re-election of Dr. Hadar Ron) and Proposal 4 (Extraordinary Special Committee Compensation) at the company's July 30 Annual General Meeting.

Why it matters — The public opposition from a major shareholder on key governance and compensation issues signals potential discord within InMode's investor base ahead of the annual meeting.

FAQ

Frequently asked questions about INMD stock

What is the INMD stock price forecast for 2026-2027?

The 5 Wall Street analysts covering InMode Ltd. have a median 12-month price target of $17, with estimates ranging from $15 to $17. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INMD stock a buy right now?

Of the 5 analysts covering InMode Ltd., 0 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks InMode Ltd. 75 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INMD?

As at 8 Oct 2026, InMode Ltd. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).

Will INMD stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +17.2% from the last close, and Ticker Nerd's factor model ranks InMode Ltd. 75 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INMD stock forecast for 2030?

No analyst covering InMode Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $17 over the next 12 months.

How has INMD stock performed over the past year?

InMode Ltd. returned -6.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does InMode Ltd. do?

InMode Ltd. is a medical technology company that develops, manufactures, and markets minimally invasive and non-invasive aesthetic treatment systems.

What is the latest news on INMD?

The most recent item we track (Seeking Alpha, 26 Sept 2026): "InMode: Hope Is Not An Effective Investment Strategy, But Neither Is Despair". Seeking Alpha covers InMode as shares remain rangebound amid declining US platform sales, though international growth and recurring consumables revenue provide some stabilization. The author maintains a 'buy' rating (downgraded from 'strong buy'), citing cyclical industry softness, macro headwinds, and frustrations with management's capital allocation, while noting the company's robust net cash, aggressive buybacks, and proprietary technology.

Company

About InMode Ltd.

InMode Ltd. is a medical technology company that develops, manufactures, and markets minimally invasive and non-invasive aesthetic treatment systems. Its current product portfolio is built around radio frequency-based platforms used in body and face contouring, skin tightening, fat reduction, skin rejuvenation, and women’s health procedures. The company also offers solutions for dermatology, plastic surgery, gynecology, otolaryngology, and ophthalmology, reflecting a broad focus across medical aesthetics and specialty care. InMode serves hospitals, clinics, and medical practices through a global distribution network, with commercial activity across the United States, Europe, Asia, and other international markets. Headquartered in Yokneam, Israel, InMode Ltd. is recognized for energy-based devices that support office-based procedures and expand treatment options in the growing aesthetic medicine market.

CEO Mr. Moshe Mizrahy · 660 employees · Israel · https://www.inmodemd.com